SC
ABCL icon

Searle & Co’s AbCellera Biologics ABCL Stock Holding History

Searle & Co’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,900
Closed -$36.1K – 178
2024
Q3 		$36.1K Sell
13,900
-1,100
-7% -$3.05K 0.01% 169
2024
Q2 		$44.4K Buy
15,000
+1,100
+8% +$4.16K 0.01% 180
2024
Q1 		$63K Hold
13,900
– – 0.02% 160
2023
Q4 		$79.4K Hold
13,900
– – 0.02% 156
2023
Q3 		$63.9K Hold
13,900
– – 0.02% 142
2023
Q2 		$107K Hold
13,900
– – 0.03% 150
2023
Q1 		$94.2K Hold
13,900
– – 0.03% 146
2022
Q4 		$141K Hold
13,900
– – 0.05% 144
2022
Q3 		$137K Hold
13,900
– – 0.05% 140
2022
Q2 		$148K Hold
13,900
– – 0.06% 144
2022
Q1 		$136K Hold
13,900
– – 0.05% 151
2021
Q4 		$199K Buy
+13,900
New +$211K 0.07% 154

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Searle & Co's ABCL Position: Q4 2024 in Review

Searle & Co sold out of AbCellera Biologics (ABCL) in Q4 2024, closing a stake of 13,900 shares — an estimated $36.1K sold.

Searle & Co first reported a position in ABCL in Q4 2021 and held it in 12 quarters. The position peaked at $199K in Q4 2021. 146 funds tracked by Wall St. Rank hold ABCL as of Q4 2024.

  • Searle & Co reported no remaining AbCellera Biologics position as of Q4 2024 after selling out during the quarter.
  • Searle & Co sold 13,900 AbCellera Biologics shares in Q4 2024, an estimated $36.1K.
  • Searle & Co first reported a position in AbCellera Biologics in Q4 2021 and held it in 12 quarters.
  • Searle & Co's AbCellera Biologics position peaked at $199K in Q4 2021.
  • 146 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2024.

Based on Searle & Co's 13F filing for Q4 2024, filed 14 Feb 2025.